← FDA DRUG APPROVALS
FDA ANDA · ANDA212362
EMPAGLIFLOZIN METFORMIN HYDROCHLORIDE
Sponsor: MSN LABS PVT LTD
APPLICATION
ANDA212362
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
None (Tentative Approval)
Products
EMPAGLIFLOZIN METFORMIN HYDROCHLORIDENone (Tentative Approval)
EMPAGLIFLOZIN 12.5MG/1000MG, METFORMIN HYDROCHLORIDE · TABLET, EXTENDED RELEASE · ORAL
EMPAGLIFLOZIN METFORMIN HYDROCHLORIDENone (Tentative Approval)
EMPAGLIFLOZIN 5MG/1000MG, METFORMIN HYDROCHLORIDE · TABLET, EXTENDED RELEASE · ORAL
EMPAGLIFLOZIN METFORMIN HYDROCHLORIDENone (Tentative Approval)
EMPAGLIFLOZIN 25MG/1000MG, METFORMIN HYDROCHLORIDE · TABLET, EXTENDED RELEASE · ORAL
EMPAGLIFLOZIN METFORMIN HYDROCHLORIDENone (Tentative Approval)
EMPAGLIFLOZIN 10MG/1000MG, METFORMIN HYDROCHLORIDE · TABLET, EXTENDED RELEASE · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.